UGT1A1 UGT1A1*28

CI-VAR-00004376Explore in graph →ClinVar 226028 CIViC 729 rs8175347

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
UGT1A1 UGT1A1*28	Belinostat	Predictive	A	Supports Adverse Response	5	accepted	EID1792 The FDA approved package insert for Belinostat recommends dose adjustment for UGT1A1*28 allele homozygotes. PMID 26313268 · Goey et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.